Bridge to Life, Ltd.

Bridge to Life, Ltd. is a privately held medical device company headquartered in Northbrook, Illinois, USA. Founded in 2005, the company's mission is to improve organ transplants by developing and licensing advanced preservation solutions and technologies. It aims to provide the highest quality of service to organ procurement organizations and transplant centers, ultimately contributing to saving lives.

The company offers a comprehensive portfolio of products designed to enhance organ viability and optimize transplant success. Key offerings include the gold-standard Belzer UW® Cold Storage Solution, Belzer MPS® UW Machine Perfusion Solution, EasiSlush® Sodium Chloride Solution, and the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System. Bridge to Life also provides the LifeCradle® Heart Preservation Transport System and various cannulas and tubing for organ perfusion.

Under the leadership of CEO Don Webber, appointed in October 2022, Bridge to Life has made significant advancements. n December 2024, the company acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System, a technology that has facilitated over 5,000 liver perfusions worldwide. The VitaSmart™ system received FDA clearance for liver transplantation in early 2026, marking a major milestone for its U.S. availability. Additionally, the company secured Breakthrough Device Designation from the FDA for its LifeCradle® Heart Preservation Transport System in April 2022. Bridge to Life continues to focus on innovation and collaboration within the transplant community, supported by a $56 million growth financing round in 2021.